Correlation of allelic loss with poor postoperative survival in breast cancer

被引：7

作者：

Emi M. ^{[1
,3
]}

Utada Y. ^{[1
,4
]}

Yoshimoto M. ^{[2
]}

Sato T. ^{[3
]}

Minobe K. ^{[1
]}

Matsumoto S. ^{[1
]}

Akiyama F. ^{[2
]}

Iwase T. ^{[2
]}

Haga S. ^{[4
]}

Kajiwara T. ^{[4
]}

Sakamoto G. ^{[2
]}

Kasumi F. ^{[2
]}

Nakamura Y. ^{[3
,5
]}

机构：

[1] Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, Nakahara-ku, Kawasaki 211-8533, 1-396, Kosugi-cno

[2] Department of Surgery and Pathology, Cancer Institute and Hospital, Japanese Foundation for Cancer Research

[3] Department of Human Genome Analysis, Cancer Institute and Hospital, Japanese Foundation for Cancer Research

[4] Department of Surgery, Daini Hospital, Tokyo Women's Medical University

[5] Laboratory of Molecular Medicine, Institute of Medical Science, University of Tokyo

来源：

Breast Cancer | 1999年 / 6卷 / 4期

关键词：

Allelic loss; Breast cancer; Postoperative survival; Prognostic marker; Tumor suppressor gene;

D O I：

10.1007/BF02966452

中图分类号：

学科分类号：

摘要：

Background: Allelic losses of tumor suppressor genes or the chromosomal regions harboring them in the DNA of tumor cells may become useful postoperative prognostic indicators. Methods: To examine whether specific allelic losses correlate with postoperative survival in a fiveyear prospective follow-up, we tested tumors from a cohort of 504 breast cancer patients for allelic loss of 1 8 microsatellite markers representing either known tumor suppressor genes or regions where genetic alterations are frequent in breast tumors. Results: Patients with allelic loss at 1 p34, 3p25, 8p22, 13q12, 17pl 3.3, or 17q21.1 had a significantly higher risks of postoperative mortality compared with those whose tumors retained both alleles at those loci (at lp34, the 5-year mortality rate was 23% among patients with loss vs 10% with retention, ρ = 0.0100; at 3p25, 22% vs 9%, ρ = 0.0014; at 8p22, 24% vs 7%, ρ = 0.0177; at 13q12, 19% vs 8%, ρ = 0.0093; at 17pl3.3, 19% vs 9%, ρ = 0.0078; and at 1 Zq 21.1, 17% vs 10%, ρ = 0.0475). Conclusion: Allelic losses at these loci can serve as negative prognostic indicators to guide postoperative management, especially in the selection of those who will benefit from intensive adjuvant therapies.

引用

页码：351 / 356

页数：5

共 31 条

[1]

Callahan R., Campbell G., Mutations in human breast cancer: An overview, Journal of the National Cancer Institute, 81, 23, pp. 1780-1786, (1989)

[2]

Knudson A.G., Anti-oncogenes and human cancer, Proc Natl Acad Sci USA, 90, pp. 10914-10921, (1993)

[3]

Harris J.R., Henderson I.C., Staging and prognostic factors, Breast Diseases, pp. 327-346, (1987)

[4]

McGuire W., Clark G., Prognostic factors and treatment decision in axillary node-negative breast cancers, N Engl J Med, 326, pp. 1756-1761, (1992)

[5]

Sato T., Tanigami A., Yamakawa K., Et al., Allelotype of breast cancer

[6]

Cumulative allele losses promote tumor progression in primary breast cancer, Cancer Res, 50, pp. 7184-7189, (1990)

[7]

Sato T., Akiyama F., Sakamoto G., Et al., Accumulation of genetic alterations and progression of primary breast cancer, Cancer Res, 51, pp. 5794-5799, (1991)

[8]

Takita K., Sato T., Miyagi M., Et al., Correlation of loss of alleles on the short Arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes, Cancer Res, 52, pp. 3914-3917, (1992)

[9]

Saito H., Inazawa J., Saito S., Kasumi F., Koi S., Sagae S., Kudo R., Saito J., Noda K., Nakamura Y., Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM Region on 17q21.3 often and commonly deleted in tumors, Cancer Research, 53, 14, pp. 3382-3385, (1993)

[10]

Harada Y., Katagiri T., Ito I., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y., Emi M., Genetic studies of 457 breast cancers: Clinicopathologic parameters compared with genetic alterations, Cancer, 74, 8, pp. 2281-2286, (1994)

← 1 2 3 4 →